Table 3.
Clinical trials employing RNA vaccines in pandemic settings.
| Study start | N | Vaccine and delivery | Outcome |
|---|---|---|---|
| NCT03014089 | ZIKA | Phase I/II | |
| Dec 2016 | 90 | mRNA 1325, modified nucleotides; LNP-formulated, Antigen: prM-E polyprotein | Results pending; estimated primary completion date in Sept 2018 |
| NCT03076385 | INFLUENZA H10N8 | Phase I | |
| Dec 2015 | 201 | mRNA 1851, modified nucleotides; LNP-formulated, Antigen: HA of H10N8 A/Jiangxi-Donghu/346/2013 | Interim results published for 100 μg IM (N = 23) vs. placebo (N = 8) Safety: acceptable safety profile Immunogenicity: - HI titers ≥40 in 100% (23/23) of subjects at day 43 - MN ≥20 in 87% (20/23) at day 43 |
| NCT03345043 | INFLUENZA H7N9 | Phase I | |
| May 2016 | 156 | mRNA 1440, modified nucleotides; LNP-formulated, Antigen: HA of H7N9 A/Anhui/1/2013 | Results pending; estimated primary completion date in Sept 2018 |
| NCT03325075 | CHIKUNGUNYA | Phase I | |
| Aug 2017 | 60 | mRNA 1388, modified nucleotides; LNP-formulated Antigen: structural polyprotein | Results pending; estimated primary completion date in Sept 2019 |
This table exclusively lists clinical trials discussed in the text; prM-E, preMembrane-Envelope; HA, Hemagglutinin; HI, hemagglutination inhibition; MN, microneutralization titers; N, number of study participants; IM, intramuscular; ID, intradermal; LNP, lipid nanoparticle.